New Oral Contraceptive Approved by FDA Feb 18, 2006
First Birth Control Pill to Provide 24 Days of Active Hormonal Therapy ROCKAWAY, N.J., Feb. 17 /PRNewswire/ -- Warner Chilcott announced today that the U.S. Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin(R) 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), for the prevention of pregnancy. Loestrin 24 Fe ("Loestrin 24") is the first birth-control pill approved in the United States that provides 24 days of active... (PR Newswire)
Paladin reports record third quarter revenue Oct 28, 2004
Paladin entered into an exclusive Canadian marketing and promotion agreement with Duramed Pharmaceuticals, Inc., a wholly-owned subsidiary of Barr Pharmaceuticals, Inc., for Loestrin(R) (norethindrone acetate 1 ... 03mg) and Minestrin(R) (norethindrone acetate 1. (Canada Newswire)
Paladin signs marketing agreement with Duramed Pharmaceuticals for two women's health products Sep 30, 2004
MONTREAL, Sept. 30 /CNW/ - Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that it has entered into an exclusive Canadian marketing and promotion agreement with Duramed Pharmaceuticals, Inc., a wholly-owned subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), for Loestrin(R) (norethindrone acetate 0 ... 03mg) and Minestrin(R) (norethindrone acetate 0. (Canada Newswire)
Leptin Effects Bone Density Independent of Hormone Replacement ... Dec 9, 2003
25 mg tibolone, and 42 participants to 2 mg estradiol plus 1 mg norethindrone acetate. All women received a daily supplementation of 500 mg of calcium with a meal during a follow-up duration of 2 years (Doctor's Guide (press release)
Low Dose Oestrogen Therapy May Not Be Safer Than Traditional ... Nov 18, 2003
Limited 2-year safety data suggest that conjugated equine oestrogen (CEE) with medroxyprogesterone acetate (as dosed in the HOPE trial), estradiol combined with norethindrone acetate (NETA) 1mg/0. 5mg, or estradiol with cyclical norgestimate 1mg/90'g do not cause unacceptable rates of hyperplasia (Doctor's Guide (press release)
